Graybug Vision (GRAY) Competitors $3.37 -0.03 (-0.88%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends GRAY vs. NRBO, PIRS, UBX, MEIP, BFRG, NNVC, TNXP, APRE, CVKD, and CARAShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include NeuroBo Pharmaceuticals (NRBO), Pieris Pharmaceuticals (PIRS), Unity Biotechnology (UBX), MEI Pharma (MEIP), Bullfrog AI (BFRG), NanoViricides (NNVC), Tonix Pharmaceuticals (TNXP), Aprea Therapeutics (APRE), Cadrenal Therapeutics (CVKD), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry. Graybug Vision vs. NeuroBo Pharmaceuticals Pieris Pharmaceuticals Unity Biotechnology MEI Pharma Bullfrog AI NanoViricides Tonix Pharmaceuticals Aprea Therapeutics Cadrenal Therapeutics Cara Therapeutics NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Does the MarketBeat Community prefer NRBO or GRAY? NeuroBo Pharmaceuticals received 11 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote. CompanyUnderperformOutperformNeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% Graybug VisionOutperform Votes1650.00% Underperform Votes1650.00% Do analysts recommend NRBO or GRAY? NeuroBo Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 323.73%. Given NeuroBo Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroBo Pharmaceuticals is more favorable than Graybug Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NRBO or GRAY more profitable? Graybug Vision's return on equity of -77.61% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroBo PharmaceuticalsN/A -189.12% -122.31% Graybug Vision N/A -77.61%-71.34% Which has more risk & volatility, NRBO or GRAY? NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Does the media refer more to NRBO or GRAY? In the previous week, NeuroBo Pharmaceuticals had 4 more articles in the media than Graybug Vision. MarketBeat recorded 4 mentions for NeuroBo Pharmaceuticals and 0 mentions for Graybug Vision. NeuroBo Pharmaceuticals' average media sentiment score of 0.84 beat Graybug Vision's score of 0.00 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment NeuroBo Pharmaceuticals Positive Graybug Vision Neutral Do institutionals and insiders believe in NRBO or GRAY? 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Graybug Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, NRBO or GRAY? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/AGraybug VisionN/AN/A-$35.60M-$24.23-0.14 SummaryNeuroBo Pharmaceuticals beats Graybug Vision on 8 of the 13 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.29M$6.56B$5.09B$8.78BDividend YieldN/A8.04%4.97%4.05%P/E Ratio-1.955.4392.1413.71Price / SalesN/A392.101,277.3288.67Price / CashN/A53.5139.5536.41Price / Book2.029.546.415.96Net Income-$35.60M$154.47M$118.66M$225.47M7 Day Performance-2.88%-3.66%-2.03%-0.84%1 Month Performance-14.90%1.85%1.42%3.80%1 Year Performance-0.83%34.27%33.98%24.95% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$3.37-0.9%N/A+0.1%$5.29MN/A-1.9527High Trading VolumeNRBONeuroBo Pharmaceuticals3.2067 of 5 stars$2.67-4.6%N/A-30.6%$21.95MN/A0.008Short Interest ↓PIRSPieris Pharmaceuticals2.537 of 5 stars$15.97-5.1%N/A-20.2%$21.08M$42.81M-0.85140UBXUnity Biotechnology4.1382 of 5 stars$1.25+6.8%N/A-26.7%$21.06M$240,000.00-0.9560Positive NewsGap UpHigh Trading VolumeMEIPMEI Pharma4.2767 of 5 stars$3.13+3.0%N/A-58.6%$20.85M$65.30M1.17100Analyst ForecastShort Interest ↑News CoverageBFRGBullfrog AI1.1748 of 5 stars$2.65+0.8%N/A-24.6%$20.80M$60,000.00-3.124Gap DownNNVCNanoViricidesN/A$1.41-2.1%N/A-1.9%$19.60MN/A-2.0120News CoverageGap UpTNXPTonix Pharmaceuticals3.0296 of 5 stars$0.14flatN/A-99.0%$19.26M$12.46M0.00103Earnings ReportAnalyst ForecastShort Interest ↑News CoverageAPREAprea Therapeutics3.2589 of 5 stars$3.52-0.8%N/A-17.3%$19.11M$580,000.00-1.257Short Interest ↑CVKDCadrenal Therapeutics1.0125 of 5 stars$17.89+0.8%N/AN/A$19.11MN/A-2.684Short Interest ↑High Trading VolumeCARACara Therapeutics4.1026 of 5 stars$0.34flatN/A-70.1%$18.70M$20.97M-0.1755Analyst ForecastShort Interest ↑News CoverageGap Down Related Companies and Tools Related Companies NRBO Competitors PIRS Competitors UBX Competitors MEIP Competitors BFRG Competitors NNVC Competitors TNXP Competitors APRE Competitors CVKD Competitors CARA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRAY) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
